The cutting edge: Promising oncology radiotracers in clinical development

IF 4.9 2区医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Diagnostic and Interventional Imaging Pub Date : 2024-05-14 DOI:10.1016/j.diii.2024.04.004

{"title":"The cutting edge: Promising oncology radiotracers in clinical development","authors":"","doi":"10.1016/j.diii.2024.04.004","DOIUrl":null,"url":null,"abstract":"<div><div><span>Molecular imaging moves forward with the development of new imaging agents<span>, and among these are new radiotracers for nuclear medicine applications, particularly positron emission tomography (PET). A number of new targets are becoming accessible for use in oncologic applications. In this review, major new radiotracers in clinical development are discussed. Prominent among these is the family of fibroblast-activation protein-targeted agents that interact with the tumor microenvironment and may show superiority to 2-deoxy-2-[18F]fluoro-</span></span><span>d</span><span>-glucose in a subset of different tumor histologies. Additionally, carbonic anhydrase IX (CAIX) inhibitors are directed at clear cell renal cell carcinoma, which has long lacked an effective PET imaging agent. Those CAIX agents may also have utility in hypoxic tumors. Pentixafor, which binds to a transmembrane receptor, may similarly allow for visualization by PET of low-grade lymphomas, as well as being a second agent for multiple myeloma that opens theranostic possibilities. There are new adrenergic agents aimed at providing a PET-visible replacement to the single-photon-emitting radiotracer meta-[123I]iodobenzylguanidine (MIBG). Finally, in response to a major development in oncologic chemotherapy, there are new radiotracers targeted at assessing the suitability or use of immunotherapeutic agents. All of these and the existing evidence for their utility are discussed.</span></div></div>","PeriodicalId":48656,"journal":{"name":"Diagnostic and Interventional Imaging","volume":null,"pages":null},"PeriodicalIF":4.9000,"publicationDate":"2024-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diagnostic and Interventional Imaging","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2211568424001062","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Molecular imaging moves forward with the development of new imaging agents, and among these are new radiotracers for nuclear medicine applications, particularly positron emission tomography (PET). A number of new targets are becoming accessible for use in oncologic applications. In this review, major new radiotracers in clinical development are discussed. Prominent among these is the family of fibroblast-activation protein-targeted agents that interact with the tumor microenvironment and may show superiority to 2-deoxy-2-[18F]fluoro-d-glucose in a subset of different tumor histologies. Additionally, carbonic anhydrase IX (CAIX) inhibitors are directed at clear cell renal cell carcinoma, which has long lacked an effective PET imaging agent. Those CAIX agents may also have utility in hypoxic tumors. Pentixafor, which binds to a transmembrane receptor, may similarly allow for visualization by PET of low-grade lymphomas, as well as being a second agent for multiple myeloma that opens theranostic possibilities. There are new adrenergic agents aimed at providing a PET-visible replacement to the single-photon-emitting radiotracer meta-[123I]iodobenzylguanidine (MIBG). Finally, in response to a major development in oncologic chemotherapy, there are new radiotracers targeted at assessing the suitability or use of immunotherapeutic agents. All of these and the existing evidence for their utility are discussed.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

最前沿：临床开发中前景看好的肿瘤放射示踪剂。

分子成像技术随着新型成像剂的开发而不断进步，其中包括用于核医学应用的新型放射性掺杂剂，特别是正电子发射断层扫描（PET）。一些新的靶点正逐渐可用于肿瘤学应用。本综述将讨论临床开发中的主要新型放射性racers。其中最突出的是成纤维细胞活化蛋白靶向制剂系列，它们与肿瘤微环境相互作用，在不同肿瘤组织学中可能显示出优于 2-脱氧-2-[18F]氟-d-葡萄糖的效果。此外，碳酸酐酶 IX（CAIX）抑制剂是针对透明细胞肾细胞癌的，而这种癌症长期以来一直缺乏有效的 PET 成像剂。这些 CAIX 抑制剂可能也适用于缺氧性肿瘤。与跨膜受体结合的 Pentixafor 同样可以通过 PET 对低级别淋巴瘤进行显像，也是治疗多发性骨髓瘤的第二种药物，为治疗提供了可能性。还有一些新的肾上腺素能药物，旨在提供一种 PET 可见剂，以替代单光子发射放射性示踪剂元[123I]碘苄胍（MIBG）。最后，为了应对肿瘤化疗的重大发展，还有一些新的放射性示踪剂用于评估免疫治疗药物的适用性或使用情况。本文讨论了所有这些放射示踪剂及其效用的现有证据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Diagnostic and Interventional Imaging Medicine-Radiology, Nuclear Medicine and Imaging

CiteScore

8.50

自引率

29.10%

发文量

126

审稿时长

11 days

期刊介绍： Diagnostic and Interventional Imaging accepts publications originating from any part of the world based only on their scientific merit. The Journal focuses on illustrated articles with great iconographic topics and aims at aiding sharpening clinical decision-making skills as well as following high research topics. All articles are published in English. Diagnostic and Interventional Imaging publishes editorials, technical notes, letters, original and review articles on abdominal, breast, cancer, cardiac, emergency, forensic medicine, head and neck, musculoskeletal, gastrointestinal, genitourinary, interventional, obstetric, pediatric, thoracic and vascular imaging, neuroradiology, nuclear medicine, as well as contrast material, computer developments, health policies and practice, and medical physics relevant to imaging.